| Name | Title | Contact Details |
|---|
Cornell University is a private Ivy League research university located in Ithaca, New York, with additional campuses in New York City and Doha, Qatar. Founded in 1865, it was established as New York’s federal land-grant institution. Cornell emphasizes inclusivity, innovation, and practical education, and it was the first Ivy League school to admit women. The university offers over 4,000 courses across more than 100 departments, providing undergraduate, graduate, and professional degrees in various fields, including engineering, agriculture, and hospitality management. Cornell is a leader in research, with over $1.3 billion in annual expenditures, focusing on areas such as life sciences and sustainability. It also engages with the public through cooperative extension programs and operates specialized campuses like Cornell Tech and Weill Cornell Medicine. With a diverse student body of over 25,000 from 120+ countries, Cornell fosters a global network of alumni, including notable figures in various fields.
CareerOneStop.org is a Saint Paul, MN-based company in the Business Services sector.
Merit Personnel Inc is a Barrie, ON-based company in the Business Services sector.
Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs.